Company news

EyePoint, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

August 7, 2024

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

August 6, 2024

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

June 25, 2024

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

June 17, 2024

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

May 7, 2024

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

May 5, 2024

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

April 1, 2024

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

March 6, 2024

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

March 3, 2024

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024

February 28, 2024

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

February 2, 2024

EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 30, 2024

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema

January 9, 2024

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints

December 3, 2023

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments

October 31, 2023

EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

October 30, 2023

EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference 2023

October 29, 2023

EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023

October 24, 2023

EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team

October 15, 2023

EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023

September 10, 2023

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

August 8, 2023

EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments

August 1, 2023

EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit

July 26, 2023

EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023

July 25, 2023

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition

July 9, 2023

EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy

June 4, 2023

EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 30, 2023

EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties

May 17, 2023

EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments

May 2, 2023

EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023

April 25, 2023

EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD

March 26, 2023

EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

March 19, 2023

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments

March 1, 2023

EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy

February 26, 2023

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023

February 22, 2023

EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

January 22, 2023

EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

January 4, 2023

EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

January 3, 2023

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

November 1, 2022

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

October 25, 2022

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

September 28, 2022

EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments

August 2, 2022

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD

July 31, 2022

EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

July 26, 2022

EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Financial Update

July 17, 2022

EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

July 14, 2022

EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022

July 10, 2022

EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors

July 10, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.